BLUEPRINT MEDICINES

blueprint-medicines-logo

Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Fou... nded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data revolution: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.

#SimilarOrganizations #People #Financial #Event #Website #More

BLUEPRINT MEDICINES

Social Links:

Industry:
Bioinformatics Biotechnology Health Care Medical

Founded:
2011-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.blueprintmedicines.com

Total Employee:
251+

Status:
Active

Contact:
617-374-7580

Email Addresses:
[email protected]

Total Funding:
1.12 B USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network


Similar Organizations

auris-health-logo

Auris Health

Auris Health engages in the development of robotics technology for medical applications.

bodycap-logo

BodyCap

BodyCap specializes in the development of miniature electronic sensors &monitors for continual measurement.

brassica-protection-products-logo

Brassica Protection Products

An innovator in the research and development of nutritional ingredients derived from cruciferous vegetables.

cerrx-logo

CerRx

CerRx engages in the discovery and development of anticancer drugs such as Fenretinide and Safingol.

editas-medicine-logo

Editas Medicine

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.

effector-therapeutics-logo

Effector Therapeutics

Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.

elite-surgical-affiliates-logo

Elite Surgical Affiliates

Elite Surgical Affiliates provides a complete spectrum of development and management services for surgery center operations.

expansion-technologies-logo

Expansion Technologies

Expansion Technologies pioneers the use of the expansion microscopy bioimaging tool for biology, medicine, and beyond.

goryo-chemical-logo

GORYO Chemical

GORYO Chemical is the only manufacturer specializing in fluorescent dyes in Japan.

idera-pharmaceuticals-logo

Idera Pharmaceuticals

Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.

koliber-biosciences-logo

Koliber Biosciences

Koliber Biosciences provides data science services including the development of predictive models for customers.

moderna-therapeutics-logo

Moderna Therapeutics

Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.

knopp-biosciences-logo

Knopp Biosciences

Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.

phoenix-biotechnology-logo

Phoenix Biotechnology

Phoenix Biotechnology engages in the research and development of therapeutic agents and treatment regimens for cancer.

semma-therapeutics-logo

Semma Therapeutics

Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.

shouti-logo

ShouTi

ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR.

theraclion-logo

Theraclion

Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound.

cogent-biosciences-logo

Cogent Biosciences

Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.

wuhan-youngsen-biotech-co-ltd-logo

WUHAN YOUNGSEN BIOTECH CO., LTD

WUHAN YOUNGSEN BIOTECH CO., LTD specializes in the research and development, production, and sales of high-end medical devices.


Current Advisors List

william-hahn_image

William Hahn Member of the Scientific Advisory Board @ Blueprint Medicines
Advisor

daniel-lynch_image

Daniel Lynch Executive Chairman of the Board of Directors @ Blueprint Medicines
Board_member
2012-11-01

scott-lowe_image

Scott Lowe Advisor @ Blueprint Medicines
Advisor

stephen-knight_image

Stephen Knight Board Of Directors @ Blueprint Medicines
Board_member

charles-rowland_image

Charles Rowland Member of the Board of Directors @ Blueprint Medicines
Board_member
2015-03-01

charles-sawyers_image

Charles Sawyers Member of the Scientific Advisory Board @ Blueprint Medicines
Advisor

david-schenkein_image

David Schenkein Member of the Board of Directors @ Blueprint Medicines
Board_member

not_available_image

Marc Lang Advisor @ Blueprint Medicines
Advisor

Current Employees Featured

brian-druker_image

Brian Druker
Brian Druker Scientific Founder @ Blueprint Medicines
Scientific Founder

alexis-borisy_image

Alexis Borisy
Alexis Borisy Director @ Blueprint Medicines
Director
2011-01-01

jeff-albers_image

Jeff Albers
Jeff Albers Chief Executive Officer @ Blueprint Medicines
Chief Executive Officer
2014-07-01

anthony-l-boral_image

Anthony L. Boral
Anthony L. Boral Chief Medical Officer @ Blueprint Medicines
Chief Medical Officer
2016-01-01

nick-lydon_image

Nick Lydon
Nick Lydon Scientific Founder @ Blueprint Medicines
Scientific Founder

christoph-lengauer_image

Christoph Lengauer
Christoph Lengauer Executive Vice President @ Blueprint Medicines
Executive Vice President
2016-11-01

steve-miller_image

Steve Miller
Steve Miller Vice President, Translational Medicine @ Blueprint Medicines
Vice President, Translational Medicine
2014-08-01

mike-landsittel_image

Mike Landsittel
Mike Landsittel Chief Financial Officer @ Blueprint Medicines
Chief Financial Officer
2019-02-01

alexis-borisy_image

Alexis Borisy
Alexis Borisy Co-Founder & Director @ Blueprint Medicines
Co-Founder & Director
2010-01-01

marion-dorsch_image

Marion Dorsch
Marion Dorsch Chief Scientific Officer @ Blueprint Medicines
Chief Scientific Officer
2016-11-01

Founder


alexis-borisy_image

Alexis Borisy

brian-druker_image

Brian Druker

chris-varma_image

Chris Varma

nick-lydon_image

Nick Lydon

Stock Details


Company's stock symbol is NASDAQ:BPMC

Acquisitions List

Date Company Article Price
2021-11-29 Lengo Therapeutics Lengo Therapeutics acquired by Blueprint Medicines 250 M USD

Investors List

redmile-group_image

Redmile Group

Redmile Group investment in Series C - Blueprint Medicines

cowen-group_image

Cowen Group

Cowen Group investment in Series C - Blueprint Medicines

partner-fund-management_image

Partner Fund Management

Partner Fund Management investment in Series C - Blueprint Medicines

tavistock-life-sciences_image

Tavistock Life Sciences

Tavistock Life Sciences investment in Series C - Blueprint Medicines

fidelity-biosciences_image

Fidelity Biosciences

Fidelity Biosciences investment in Series C - Blueprint Medicines

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series C - Blueprint Medicines

nextech-invest_image

Nextech Invest

Nextech Invest investment in Series C - Blueprint Medicines

casdin-capital_image

Casdin Capital

Casdin Capital investment in Series C - Blueprint Medicines

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series C - Blueprint Medicines

third-rock-ventures_image

Third Rock Ventures

Third Rock Ventures investment in Series C - Blueprint Medicines

Official Site Inspections

http://www.blueprintmedicines.com Semrush global rank: 1.92 M Semrush visits lastest month: 11.36 K

  • Host name: 23.185.0.1
  • IP address: 23.185.0.1
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Blueprint Medicines"

About - Blueprint Medicines

Striving to improve and extend patientsโ€™ lives. Blueprint Medicines is a global biopharmaceutical company that invents life-changing medicines.See details»

Medical professionals - Blueprint Medicines

A team within Blueprint Medicines' global Medical Affairs organization is collaborating with research partners to use โ€˜real-worldโ€™ evidence from numerous sources to help providers more quickly identify and diagnose patients with โ€ฆSee details»

Blueprint Medicines Company Profile | Management and

SQL International Organization for Standardization . CSS World Wide Web Consortium . Java Oracle . Python Python Software Foundation . ... [email protected]: Blueprint โ€ฆSee details»

Blueprint Medicines - Crunchbase Company Profile

Contact Email [email protected] Phone Number 617-374-7580 Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular โ€ฆSee details»

Board of Directors - Blueprint Medicines Corp.

[email protected] Media contacts Andrew Law Senior Director, Global Business Communications 617.844.8205 Jessica Mullan Director, Corporate Communications โ€ฆSee details»

Blueprint Medicines - LinkedIn

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical โ€ฆSee details»

Blueprint Medicines - Craft

Oct 29, 2024 Blueprint Medicines has 5 employees across 4 locations and $249.38 m in annual revenue in FY 2023. See insights on Blueprint Medicines including office locations, โ€ฆSee details»

Our mission and values - Blueprint Medicines

2022. We announced plans to expand our scientific platform to include targeted protein degradation, a therapeutic modality that complements and leverages our capability and โ€ฆSee details»

Overview | Blueprint Medicines Corp.

Oct 30, 2024 [email protected]. Overview Recent news Dec 18, 2024 Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference. Dec 07, 2024 โ€ฆSee details»

Blueprint Medicines Corp - Company Profile - GlobalData

Blueprint Medicines Corp (Blueprint Medicines) is a biopharmaceutical company that discovers, develops and commercializes innovative therapies for allergy, inflammation, cancer and blood โ€ฆSee details»

Blueprint Medicines - Fortune

Figures are for latest twelve months ended Sept. 30, 2024. Market value as of Nov. 20, 2024.See details»

A Brief History of Blueprint Medicines โ€“ CBM

Oct 2, 2024 Website: https://www.blueprintmedicines.com; Focus: Discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets; Over the years, โ€ฆSee details»

Our Blueprint | Blueprint Medicines

An interview with Amy Monpara and Rahul Kalathiya, Senior Medical Science Liaisons Across our organization, teams work together in pursuit of a common goal toโ€ฆ Read more Our dedication โ€ฆSee details»

Search Medical Information | Blueprint Medicines | HCP Site

To report an adverse reaction or product complaint, call 1-888-BLUPRNT, option 2, or visit or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.See details»

Blueprint Medicines Announces "2020 Blueprint" Global Business โ€ฆ

CAMBRIDGE, Mass., Jan. 4, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases โ€ฆSee details»

Our responsibility - Blueprint Medicines

We support: Tools and resources to help employees prioritize health, financial and overall wellbeing, including a Work Well Program focused on finding harmony between work and life, โ€ฆSee details»

Events and presentations | Blueprint Medicines Corp.

Nov 21, 2024 [email protected] Media contacts Andrew Law Senior Director, Global Business Communications 617.844.8205 Jessica Mullan Director, Corporate Communications โ€ฆSee details»

Our approach | Blueprint Medicines

Our company was founded with the idea that research and development of innovative medicines could be accelerated. To bring this idea to life, we created a new, proprietary scientific platform โ€ฆSee details»

Blueprint Medicines Data Highlight Clinical Leadership in Systemic ...

Apr 12, 2021 Andrew Law, 617-844-8205, [email protected]; Investor Relations Contact, Kristin Hodous, 617-714-6674, [email protected] Investor contacts Jenna โ€ฆSee details»

linkstock.net © 2022. All rights reserved